105 related articles for article (PubMed ID: 16475167)
1. Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy.
Hoffmann S; Wunderlich A; Celik I; Maschuw K; Hassan I; Hofbauer LC; Zielke A
J Cell Biochem; 2006 Jul; 98(4):954-65. PubMed ID: 16475167
[TBL] [Abstract][Full Text] [Related]
2. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes.
Straight AM; Oakley K; Moores R; Bauer AJ; Patel A; Tuttle RM; Jimeno J; Francis GL
Cancer Chemother Pharmacol; 2006 Jan; 57(1):7-14. PubMed ID: 16001179
[TBL] [Abstract][Full Text] [Related]
3. Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells.
Hoffmann S; Rockenstein A; Ramaswamy A; Celik I; Wunderlich A; Lingelbach S; Hofbauer LC; Zielke A
Mol Cell Endocrinol; 2007 Jan; 264(1-2):74-81. PubMed ID: 17101211
[TBL] [Abstract][Full Text] [Related]
4. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
5. Expression of angiogenesis inhibitors in human bladder cancer may explain rapid metastatic progression after radical cystectomy.
Beecken WD; Engl T; Jonas D; Blaheta RA
Int J Mol Med; 2009 Feb; 23(2):261-6. PubMed ID: 19148551
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis--a new target for future therapy.
Pandya NM; Dhalla NS; Santani DD
Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
[TBL] [Abstract][Full Text] [Related]
7. Expression and secretion of endostatin in thyroid cancer.
Hoffmann S; Wunderlich A; Lingelbach S; Musholt PB; Musholt TJ; von Wasielewski R; Zielke A
Ann Surg Oncol; 2008 Dec; 15(12):3601-8. PubMed ID: 18818971
[TBL] [Abstract][Full Text] [Related]
8. The novel targets for anti-angiogenesis of genistein on human cancer cells.
Su SJ; Yeh TM; Chuang WJ; Ho CL; Chang KL; Cheng HL; Liu HS; Cheng HL; Hsu PY; Chow NH
Biochem Pharmacol; 2005 Jan; 69(2):307-18. PubMed ID: 15627483
[TBL] [Abstract][Full Text] [Related]
9. Ganoderma tsugae extract inhibits expression of epidermal growth factor receptor and angiogenesis in human epidermoid carcinoma cells: In vitro and in vivo.
Hsu SC; Ou CC; Chuang TC; Li JW; Lee YJ; Wang V; Liu JY; Chen CS; Lin SC; Kao MC
Cancer Lett; 2009 Aug; 281(1):108-16. PubMed ID: 19332363
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic function of tocotrienol.
Miyazawa T; Shibata A; Nakagawa K; Tsuzuki T
Asia Pac J Clin Nutr; 2008; 17 Suppl 1():253-6. PubMed ID: 18296349
[TBL] [Abstract][Full Text] [Related]
11. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis.
Avnet S; Cenni E; Perut F; Granchi D; Brandi ML; Giunti A; Baldini N
Int J Oncol; 2007 Feb; 30(2):469-76. PubMed ID: 17203230
[TBL] [Abstract][Full Text] [Related]
13. Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol.
Shibata A; Nakagawa K; Sookwong P; Tsuzuki T; Oikawa S; Miyazawa T
Biochem Pharmacol; 2008 Aug; 76(3):330-9. PubMed ID: 18599020
[TBL] [Abstract][Full Text] [Related]
14. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
Balthasar S; Bergelin N; Löf C; Vainio M; Andersson S; Törnquist K
Endocr Relat Cancer; 2008 Jun; 15(2):521-34. PubMed ID: 18509004
[TBL] [Abstract][Full Text] [Related]
15. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
16. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.
Kimura Y; Sumiyoshi M; Baba K
Cancer Sci; 2008 Oct; 99(10):2083-96. PubMed ID: 19016770
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel anti-angiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)-differentiated glioblastoma cells.
Moreno MJ; Ball M; Andrade MF; McDermid A; Stanimirovic DB
Glia; 2006 Jun; 53(8):845-57. PubMed ID: 16586492
[TBL] [Abstract][Full Text] [Related]
19. A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway.
Zhu W; Ou Y; Li Y; Xiao R; Shu M; Zhou Y; Xie J; He S; Qiu P; Yan G
Mol Pharmacol; 2009 Apr; 75(4):812-9. PubMed ID: 19158360
[TBL] [Abstract][Full Text] [Related]
20. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
